Artivion Inc, a cardiac and vascular solutions company, has received mixed analyst ratings with an average 12-month price target of $43.83. The company shows strong financial performance with impressive revenue growth, net margin, and efficient asset utilization.

Artivion reported strong Q2 2025 financial results, with non-GAAP EPS of $0.24, exceeding expectations and growing 243% year-over-year. Revenue reached $113.0 million, a 15% increase, and the company raised its full-year 2025 guidance.

Artivion, Inc. experienced a data breach on November 20-21, 2024, where an unauthorized third party accessed network files potentially containing sensitive personal information like Social Security Numbers and driver's license details.

The global organ preservation solution market is expected to grow from $273.96 million in 2023 to $536.73 million in 2033, driven by factors such as the rise in organ transplant surgeries, favorable government regulations, and the growing prevalence of chronic diseases. The report highlights key market trends, including strategic investments in R&D, partnerships, and the establishment of new research centers to drive innovation in organ preservation techniques.

The global Wound Closure Market is expected to grow from $15.17 billion in 2023 to $26.63 billion by 2032, driven by increasing chronic wounds, aging population, and rising healthcare infrastructure. Sutures and hemostatic agents are the key product types, with general surgery and cardiology being the major application areas.

In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Frank Takkinen Lake Street Raises Buy $30.00 $28.00 Rick Wise Stifel Raises Buy $25.00 $22.00 Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.com

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

4 analysts have expressed a variety of opinions on Artivion (NYSE:AORT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.5, a high estimate of $30.00, and a low estimate of $22.00. Marking an increase of 10.87%, the current average surpasses the previous average price target of $23.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Rick Wise Stifel Raises Buy $22.00 $20.00 Mike Matson Needham Raises Buy $25.00 $22.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. ...Full story available on Benzinga.com

Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.